FibroGen (NASDAQ:FGEN) Issues Earnings Results

FibroGen (NASDAQ:FGEN) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06, Zacks reports.

FibroGen Trading Up 1.3 %

FGEN traded up $0.01 during trading on Monday, hitting $0.45. 1,363,565 shares of the company’s stock were exchanged, compared to its average volume of 2,320,349. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.80. The stock has a 50 day moving average price of $0.51 and a 200 day moving average price of $0.43. The firm has a market cap of $44.84 million, a P/E ratio of -0.36 and a beta of 0.82.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on FGEN shares. StockNews.com started coverage on shares of FibroGen in a research note on Friday. They set a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of FibroGen in a research note on Thursday, February 20th.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.